<DOC>
	<DOC>NCT02172105</DOC>
	<brief_summary>Study to evaluate safety, tolerability, and pharmacokinetics of BI 1744 CL in healthy Japanese male volunteers.</brief_summary>
	<brief_title>Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Healthy Japanese men: According to the results of a complete medical history, the physical examination, vital signs (blood pressure and pulse rate), 12lead ECG, clinical laboratory tests Age ≥20 and ≤35 years Body mass index (BMI) ≥18.5 and ≤25.0 kg/m2 Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation Subjects must be able to inhale medication in a competent manner from the Respimat®inhaler Any finding of the medical examination (including ,blood pressure and pulse rate and ECG) deviating from normal and of clinical relevance Any evidence of a clinically relevant concomitant disease Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Surgery of the gastrointestinal tract (except appendectomy) Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History of relevant orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) Intake of drugs with a long halflife (&gt;24 hours) within at least one month or less than 10 halflives of the respective drug before drug administration or during the trial Use of prescription or nonprescription drugs within 10 days before drug administration or during the trial. However, overthecounter drugs for external application (such as lubricant eye drops for contact lens, insect bite reliever) shall be allowed Participation in another trial with an investigational drug within four months before drug administration or during the trial Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day) Inability to refrain from smoking on trial days Alcohol abuse (more than 60 g/day: corresponds to ca. 3 large bottles of beer, 3 gous (ca. 540 cc) of Japanese sake, 6 shots of whisky, 6 glasses of wine or 6 glasses of Japanese shochu, distilled alcoholic beverage) Drug abuse Blood donation (more than 100 mL within four weeks before drug administration or during the trial) Excessive physical activities (within one week before administration or during the trial) Any laboratory value outside the reference range that is of clinical relevance Inability to comply with dietary regimen of trial site A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval &gt;450 ms) or long QT syndroms A history of additional risk factors for torsades de pointes (TdP) (e.g., heart failure, hypokalemia) or other cardiac arrhythmias hyperthyroidism Disagree with adequate contraception (the subject should use condoms and his partner should use oral contraception or intrauterine device [IUD]) during the study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>